These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11167651)

  • 1. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1).
    Hayes MC; Birch BR; Cooper AJ; Primrose JN
    BJU Int; 2001 Feb; 87(3):245-50. PubMed ID: 11167651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.
    Pagliarulo V; Ancona P; Niso M; Colabufo NA; Contino M; Cormio L; Azzariti A; Pagliarulo A
    Mol Cancer; 2013 May; 12():47. PubMed ID: 23705854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines.
    Yu DS; Chang SY; Ma CP
    Br J Urol; 1998 Oct; 82(4):544-7. PubMed ID: 9806185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
    Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
    BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
    Solomon LZ; Jennings AM; Foley SJ; Birch BR; Cooper AJ
    Br J Urol; 1998 Jul; 82(1):122-6. PubMed ID: 9698674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
    Birare N; Lwaleed BA; Cooper AJ
    J Urol; 2009 Nov; 182(5):2472-6. PubMed ID: 19765756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
    Pu YS; Hsieh TS; Cheng AL; Tseng NF; Su IJ; Hsieh CY; Lai MK; Tsai TC
    Br J Urol; 1996 Jan; 77(1):76-85. PubMed ID: 8653321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone: a novel adjunct to intravesical chemotherapy.
    Lewin J; Cooper A; Birch B
    BJU Int; 2002 Nov; 90(7):736-41. PubMed ID: 12410758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
    Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
    Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estramustine reversal of resistance to intravesical epirubicin chemotherapy.
    Jennings AM; Solomon LZ; Sharpe P; Hayes MC; Cooper AJ; Birch BR
    Eur Urol; 1999 Apr; 35(4):327-35. PubMed ID: 10087397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
    Speers AG; Lwaleed BA; Featherstone JM; Cooper AJ
    J Urol; 2007 Nov; 178(5):2171-5. PubMed ID: 17870115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of mitomycin C-induced multidrug resistance in vitro.
    Dorr RT; Liddil JD
    Cancer Chemother Pharmacol; 1991; 27(4):290-4. PubMed ID: 1671830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
    Qiu ZQ; Qiu ZR
    Asian Pac J Cancer Prev; 2015; 16(8):3447-50. PubMed ID: 25921160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
    Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
    Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
    Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
    BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitrotriazole AK-2123 enhances mitomycin C activity in mice bearing multidrug-resistant tumors.
    Goncharova SA; Rajewskaya TA; Konovalova NP; Kagiya TV
    J Chemother; 2001 Dec; 13(6):635-40. PubMed ID: 11806625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.
    Zalipsky S; Saad M; Kiwan R; Ber E; Yu N; Minko T
    J Drug Target; 2007; 15(7-8):518-30. PubMed ID: 17671898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.